Lawsuit Information Center
A spinal cord stimulator is an implantable medical device used to manage chronic pain, most often involving the back or spine. These systems are marketed as a way to reduce pain by interrupting nerve signals before they reach the brain. But for a growing number of patients, the device does not just fail to help. It introduces new and sometimes permanent problems, including electrical shocks, burning pain, infections, lead migration, hardware failure, and repeat surgeries to reposition or remove equipment that was supposed to improve quality of life.
This page explains spinal cord stimulator lawsuits and why they are being filed nationwide. It focuses on what patients are alleging, how these devices have failed in real-world use, and why many of these cases go beyond ordinary medical malpractice claims. The most serious lawsuits do not center on a single surgical mistake. They examine how modern spinal cord stimulators were designed, tested, and approved, and whether patients were ever adequately warned about the risks that now recur repeatedly in medical records and FDA reports.
Many people arrive here with a practical question in mind: what do spinal cord stimulator settlement amounts look like, and how does compensation get calculated when a device causes lasting harm? That question cannot be answered in isolation. Settlement amounts and payouts are driven by the full medical timeline, including the cost of repeat surgeries, explantation, permanent loss of function, and the downstream consequences when a pain-management device leaves someone worse off than before it was implanted.
What follows is a detailed breakdown of the allegations, the regulatory history behind these devices, the types of injuries being reported, and how spinal cord stimulator compensation is evaluated in serious cases.
If you or a loved one suffered complications after implantation, this page is meant to help you understand not just whether you may have a claim, but why these cases are being taken seriously across the country.
Get a free no-obligation consultation or call us today at 800-553-8082.
Spinal Cord Stimulator Lawsuit Updates
April 1, 2026 – Medtronic Wins Spinal Stimulator Case
Medtronic just won another spinal cord stimulator case, with the Ninth Circuit holding that a Washington plaintiff could not proceed because he lacked expert testimony linking his injuries to the company’s conduct.
The plaintiff said the implant malfunctioned, worsened his pain, and was never properly serviced, but the court said that was not enough under Washington law without qualified expert proof on causation.
Unlike the Boston Scientific case we discuss below in the March 22 update, which turned on preemption, this one turned on a simpler but equally fatal problem. The plaintiff could not prove the device maker caused the harm he alleged. For injured patients, the result is the same either way. Another serious device case is gone without a trial.
Medtronic’s luck will run out as we carefully prepare these lawsuits for trial.
March 22, 2026 – Abbott Proclaim XR5 Lawsuit Alleges Reprogramming by Sales Reps, Repeat Lead Migration, and Explant
A new spinal cord stimulator lawsuit filed in the Northern District of Illinois targets Abbott and its Proclaim XR5 system, and the allegations go beyond the usual device-failure narrative. The plaintiff was told by Abbott sales representatives before implantation that the permanent Proclaim XR5 would provide long-term pain relief, was clinically validated, and would work as well as or better than the temporary trial stimulator. The lawsuit says those promises turned out to be false after the permanent implant allegedly failed to provide lasting relief and instead led to worsening pain and repeated complications.
The complaint also focuses heavily on Abbott’s post-implantation conduct. The plaintiff says that Abbott representatives repeatedly programmed and reprogrammed the device after surgery, at times without meaningful physician supervision, and later instructed her by phone on how to make therapeutic adjustments herself. These representatives were treated as the only people who could properly manage the system, and their guidance kept the plaintiff from recognizing sooner that the device was failing. That is an important wrinkle because it pushes the case beyond a standard product defect claim and into allegations that company representatives were directly shaping treatment decisions after implantation — which just should not happen.
Lead migration is another major theme in the lawsuit. The plaintiff alleges that one lead was found to have migrated in July 2023, which led to revision surgery the following month. But the problems did not stop there. After the revision, the plaintiff again lost pain relief and asked whether the leads could have moved again. She says Abbott representatives told her there was no way that had happened and instead increased the stimulation settings. A doctor then discovered a second lead migration in September 2023. By March 2024, the plaintiff says the Proclaim XR5 had to be surgically removed because it had completely lost therapeutic efficacy.
This complaint echoes the broader regulatory theory you are going to see in these claims. The Proclaim XR5 was marketed under a PMA lineage that dates back to a much older device approved in 2001, even though Abbott and its predecessors allegedly made more than 230 supplemental changes involving firmware, waveform architecture, battery design, wireless programming, and other core functions without submitting a new PMA. The complaint further points to Class I recalls involving Abbott Proclaim devices and argues that the current system was materially different from the one originally approved, while patients and doctors were never fully warned about the evolving risks.
February 27, 2026 – Spinal Cord Stimulator Lawsuit Dismissed
A Michigan federal judge on Tuesday tossed a WaveWriter spinal cord stimulator case against Boston Scientific, finding the claims preempted under the FDCA and the Medical Device Amendments because the device went through FDA Premarket Approval.
The plaintiff alleged the implant stopped working as intended, produced painful, shocking sensations after revisions, could not be successfully reprogrammed, and ultimately had to be removed, leaving lasting nerve symptoms. He sued on failure to warn and manufacturing defect theories, arguing the company should have responded to post-market safety signals and that the device was not made in compliance with the federally approved specifications.
The court held that the warning theory would require different or additional warnings beyond FDA-approved labeling and that the manufacturing and negligence theories were not tied to a specific parallel Michigan duty, so the case was dismissed with prejudice.
Preemption is the defense argument that federal device regulation overrides state tort claims for PMA Class III devices unless a plaintiff fits through a narrow gap: a traditional state law claim that mirrors a concrete federal requirement. The problem is that this approach often demands granular quality system facts at the pleading stage that plaintiffs typically cannot access without discovery, effectively turning the manufacturer’s control of information into a shield.
If higher courts adopt this reasoning broadly, it will shrink these spinal stimulator cases to a small subset of tightly pleaded manufacturing deviation claims and weaken leverage across the litigation.
We do not think preemption will apply as a blanket bar here because PMA approval is not a lifetime immunity deal, and companies still have to follow the rules and respond to what they learn after the device is on the market.
February 19, 2026 – Spinal Cord Stimulator MDL Sought
A group of plaintiffs has asked the U.S. Judicial Panel on Multidistrict Litigation to consolidate all federal lawsuits involving Abbott and Boston Scientific spinal cord stimulators into an MDL in the Northern District of Illinois.
The motion, filed under 28 U.S.C. § 1407, seeks to centralize at least fifteen pending cases across five jurisdictions, most of which also name the FDA under the Administrative Procedure Act.
Plaintiffs argue that the cases share core factual and legal questions involving device design, federal regulatory compliance, and preemption defenses, and that consolidation would prevent inconsistent rulings and duplicative discovery. No court has yet ruled on key motions, including federal preemption defenses that are already fully briefed in at least one case.
The lawsuits allege that Abbott’s spinal cord stimulator line traces back to the Genesis system approved in 2001 under PMA P010032, and Boston Scientific’s line to the Precision system approved in 2004 under PMA P030017. Plaintiffs contend that neither original approval was supported by independent clinical trial data specific to the devices. Instead, the FDA allegedly relied on published literature involving other manufacturers’ systems.
Since then, both companies have introduced successive generations of stimulators through PMA supplements rather than new PMA applications, despite incorporating substantial changes such as multiwaveform stimulation modes, posture-adaptive programming, expanded electrode arrays, Bluetooth-enabled interfaces, revised battery architecture, and redesigned leads. Plaintiffs argue these modifications fundamentally altered the devices’ safety profiles while avoiding the more rigorous scrutiny required for new Class III approvals.
This is a big problem. The FDA received a stunning 107,728 adverse event reports related to spinal cord stimulators over a four-year period, including more than 30,000 complaints of unsatisfactory pain relief. Plaintiffs allege that the agency failed to meaningfully review supplemental approvals and unlawfully permitted manufacturers to bring materially different devices to market through a regulatory shortcut.
Every spinal cord stimulator lawsuit asserts injuries, including lead migration, electrical shocks, burning sensations, neurological injury, autonomic dysfunction, and chronic pain exacerbation. With roughly 50,000 spinal cord stimulators implanted annually and the two companies controlling a majority market share, plaintiffs argue that tens of thousands of additional claims may exist. They contend that consolidating the cases in Illinois, where Abbott is headquartered and multiple actions are already pending, would promote judicial economy and ensure consistent rulings on preemption and regulatory oversight issues.
February 2, 2026 – New Spinal Cord Stimulator Lawsuit
A new spinal cord stimulator lawsuit was filed alleging that a Boston Scientific spinal cord stimulator battery malfunctioned and required surgical removal after the device failed and caused worsening pain and complications. This adds to litigation over implanted neuromodulation devices that plaintiffs say did not perform as represented and led to additional procedures.
October 17, 2026 – Spinal Cord Lawsuit in California
A federal lawsuit was filed in the Central District of California against Boston Scientific and the FDA over the Spectra WaveWriter device. The complaint alleges that lead migration and subsequent complications, including cardiac arrhythmia, resulted from substantial device modifications that improperly used the FDA’s PMA supplement pathway instead of requiring a full PMA review. The plaintiff is seeking damages and a jury trial.
Spinal Cord Stimulators
Spinal cord stimulation devices are Class III implantable neuromodulation systems intended to deliver controlled electrical impulses to the spinal cord to manage chronic, intractable pain. These systems generally include an implantable pulse generator, one or more electrical leads placed near the spinal cord, and an external controller that allows the patient to adjust stimulation levels.
The theory behind spinal cord stimulation is that targeted electrical impulses applied to the dorsal columns of the spinal cord can interfere with or alter the transmission of pain signals before they reach the brain. By modulating these signals, the devices are intended to provide relief for patients whose pain has not responded to more conventional treatment options.
Despite their intended benefits, spinal cord stimulation systems carry significant and well-documented risks. Reported complications include device migration, lead fracture or displacement, battery malfunction, infection, neurological injury related to stimulation, worsening pain, and autonomic dysfunction.
Because of these substantial risks, the FDA classifies spinal cord stimulation systems as Class III medical devices. This designation requires rigorous Premarket Approval and supplemental review for any design or functional modifications that could affect the device’s safety or effectiveness.
Spinal Cord Stimulator Lawsuits: Allegations of Defective Medical Devices
Across the United States, patients are filing lawsuits involving spinal cord stimulators (SCS), alleging these implantable pain-management devices were defectively designed and unreasonably dangerous. According to FDA adverse-event data, thousands of complaints have been reported involving spinal cord stimulators, including burns, infections, device migration, electrical malfunction, and the need for repeated corrective surgeries.
Major manufacturers—including Boston Scientific, Medtronic, Abbott, and Nevro Corp—are accused of failing to adequately warn patients and physicians about known risks associated with these devices. Independent scientific studies have raised concerns that spinal cord stimulators are prone to lead migration, hardware failure, and electrical defects, which can result in serious neurological injury and long-term complications.
Many patients report they were never fully informed of these dangers before implantation. After suffering burns, infections, worsening pain, paralysis, or undergoing revision surgeries or complete device removal, patients often face significant physical pain, emotional distress, and financial hardship. As a result, injured individuals and their families are pursuing spinal cord stimulator lawsuits to seek compensation and accountability.
What separates spinal cord stimulator lawsuits from ordinary medical malpractice cases is not just the severity of the injuries, but the regulatory and design history behind these devices. Many of the most serious claims now being filed do not focus solely on surgical error or isolated malfunction. Instead, they examine how modern spinal cord stimulators were approved, how dramatically they changed over time, and whether patients were ever protected by the safety testing they were led to believe occurred.
Reported Spinal Cord Stimulator Complications
Spinal cord stimulator injuries being alleged in lawsuits include:
Common Alleged Injuries and Complications
One reported case involved an elderly patient, whom we talk about below, who developed Ogilvie syndrome following implantation. The complication progressed to bowel rupture and multi-organ failure. While causation remains disputed, similar autonomic complications have been reported following neuromodulation procedures.
Another lawsuit alleges a WaveWriter Alpha stimulator migrated and delivered painful shocks, with company representatives allegedly adjusting the device without a physician present.
These fact patterns are not identical. But the themes are consistent: device movement, electrical malfunction, worsening symptoms, and inadequate warning.
How FDA Approval Is Being Used As A Shield
One of the first things spinal cord stimulator manufacturers point to when patients are injured is FDA approval. The implication is simple and powerful: the device was approved, therefore it must be safe. But that framing omits how spinal cord stimulators reached the market and how they have evolved.
Spinal cord stimulators are classified as Class III medical devices, the highest risk category under federal law. So in theory, that classification means the device must undergo rigorous premarket approval, including clinical testing, before it can be sold. This is as it should be, right? In practice, many of today’s spinal cord stimulators trace their approval back to much older devices, approved decades ago, through a regulatory pathway that allows manufacturers to make changes without submitting new clinical evidence each time.
Manufacturers are permitted to update devices through PMA supplements. These are intended to cover limited, incremental changes that do not meaningfully alter how a device works or how risky it is. The problem arises when companies rely on this process to roll out sweeping design changes over many years without ever returning to the FDA for a full review.
In the spinal cord stimulator space, manufacturers have introduced major modifications to battery systems, lead designs, stimulation waveforms, wireless communication features, posture-adaptive algorithms, and multi-source current delivery. These are not cosmetic tweaks. They directly affect how electrical signals are delivered to the spinal cord and how the device behaves inside the body.
Yet many of these changes were cleared through paperwork rather than new human trials. As a result, patients may be implanted with devices that are materially different from the versions originally approved, even though the FDA approval label remains the same. From the patient’s perspective, the device appears fully vetted. From a regulatory standpoint, the safety data often lags far behind the technology.
This regulatory gap matters in real-world terms. When a device malfunctions, migrates, overheats, or delivers unintended electrical shocks, manufacturers often argue that these outcomes fall within “known risks.” But a risk cannot be meaningfully known if the device has evolved beyond the version that was ever properly studied.
Lawsuits now being filed across the country allege that manufacturers exploited this regulatory structure by stacking change upon change without conducting the testing needed to reveal long-term failure rates or rare but devastating complications. Plaintiffs also allege that warnings never reflected how these newer systems behaved once implanted in patients.
The result is a familiar pattern in modern medical device litigation. FDA approval becomes a talking point, not a safeguard. Devices reach patients faster than the science can keep up, and serious complications are only fully recognized after thousands of people have already been exposed.
This is why many spinal cord stimulator lawsuits focus not just on individual injuries but also on whether manufacturers complied with the spirit and intent of the regulatory system. The core allegation is not that innovation is bad. It is that innovation without accountability shifts the risk onto patients who never agreed to be test subjects.
Elderly Patient Dies After Colon Complication Following SCS Implant
In mid-December, an elderly man received a spinal cord stimulator to treat chronic pain. Shortly after implantation, he developed Ogilvie’s syndrome. This complication in elderly or medically fragile patients after surgery or neurologic interference. It has been reported in connection with spinal procedures and neuromodulation, including SCS implantation, particularly when autonomic nerve function is affected.
The swelling in this patient, unfortunately, became so severe that it ruptured his cecum, triggered multiple organ failure, and ultimately led to his death. The condition is believed to be linked to complications from the spinal cord stimulator. Similar reports involving electrocution, infections, and device migration have prompted patients and families nationwide to pursue legal claims against device manufacturers.
Virginia Woman Sues FDA and Boston Scientific Over Defective Device
A Virginia woman has filed a spinal cord simulator lawsuit against Boston Scientific and the U.S. Food and Drug Administration, alleging that a defective spinal cord stimulator caused severe and worsening injuries after implantation.
According to the complaint, the woman received a WaveWriter Alpha spinal cord stimulator to manage chronic pain, but instead, it made things worse, and she experienced electrical shocks, device migration, and escalating physical harm.
The lawsuit further alleges that the device moved from its intended position and delivered painful electrical impulses that were not only ineffective but also dangerous. Doctors sometimes call this migration, and it can cause real damage to the patient in many different contexts
The patient also claims that company representatives adjusted and altered the device without her physician present, dismissing her concerns even as her condition deteriorated. If you are following this medical device, you would not be surprised, as the allegations mirror reports documented in FDA adverse-event data, in which other patients have described similar injuries linked to the same device system.
In addition to claims against the manufacturer, the lawsuit raises serious questions about regulatory oversight. The plaintiff alleges that Boston Scientific continued to market and sell a spinal cord stimulator that materially differed from the version originally approved by the FDA, without undergoing proper supplemental review or safety testing. The complaint asserts that these changes increased the risk of injury while depriving patients and physicians of critical information needed to make informed decisions.
The case highlights a growing concern in spinal cord stimulator litigation: that device manufacturers may prioritize speed to market and continued sales over patient safety, while regulators fail to intervene despite mounting evidence of harm. Although the case remains pending, it reflects broader allegations being raised nationwide by patients who say they were never adequately warned about the risks associated with these devices—and who now face lasting pain, repeated procedures, and diminished quality of life.
When Device Reps Cross the Line Into Treatment
One of the more serious issues emerging in spinal cord stimulator litigation is that some lawsuits are not just about the device itself. They focus on the role manufacturer representatives play before and after implantation. The claim is that these representatives are not merely providing technical support. In some cases, they are accused of helping sell the implant by making assurances about long-term pain relief, clinical validation, and expected performance, then remaining heavily involved once problems begin.
So this is a different twist. A spinal cord stimulator lawsuit may no longer be just about whether the hardware malfunctioned. It might also be about whether patients were influenced by sales-driven promises and then steered through repeated reprogramming efforts instead of getting a candid assessment that the device was failing from their unbiased healthcare providers.
So we allege that manufacturer representatives have taken an active role in programming and reprogramming spinal cord stimulators after implantation, sometimes across multiple visits and sometimes with only limited physician involvement. This kind of involvement can clearly blur the line between product support and treatment, especially when the representative is the person the patient is told to rely on when pain worsens, stimulation becomes erratic, or the device stops delivering relief.
These allegations become even more troubling when paired with claims of lead migration, electrical shocks, or sudden loss of therapeutic benefit. One of the recurring themes in the spinal stimulator lawsuits is that repeated device adjustments may be used as a temporary response to serious complications, even when the underlying issue may be hardware movement, system instability, or loss of efficacy that reprogramming cannot fix. This looks less like troubleshooting and more like a delay.
This strengthens several types of claims at once. It can support allegations involving negligent misrepresentation, breach of warranty, failure to warn, and broader negligence theories tied to post-implant conduct. It also gives juries a more concrete story. Instead of hearing only that a device failed, they hear that the manufacturer may have remained deeply involved while the patient’s condition worsened.
Abbott Recall History and Warning Failures
Another issue likely to matter in spinal cord stimulator litigation is whether patients and doctors were ever given a fair warning about how newer Abbott systems actually performed in the real world. The Abbott spinal cord stimulator lawsuits being filed do not just allege that these devices could fail in a general sense. We allege that important risks were understated, poorly communicated, or buried beneath broad assurances about safety and effectiveness.
Spinal cord stimulator complications are not limited to a disappointing result. Painful electrical shocks, sudden loss of therapy, charging failures, communication problems between device components, lead migration, and worsening pain are all things patients have reported after implantation. In a device intended to treat chronic pain, those are not minor side effects. They go to the core question of whether the product was functioning safely at all.
Abbott also draws added scrutiny because of its recall history involving serious device problems. FDA Class I recalls are the agency’s most serious recall category, and recent complaints point to Proclaim-related recalls involving issues such as unintended painful stimulation, device shutdowns, and failure to deliver therapy. Plaintiffs argue that a recall history like this undercuts any suggestion that the reported problems are isolated or speculative.
The broader allegation is that the warnings never kept pace with the technology. As spinal cord stimulator systems evolved through repeated supplemental changes to firmware, battery architecture, wireless programming, and stimulation features, our contention is that the risks evolved too. But, as our lawsuits argue, patients were still not clearly told that the device being implanted may have been materially different from the version originally approved years earlier.
That warning gap is a big deal in these cases. A manufacturer does not get much mileage out of saying a risk was technically known if the actual device changed over time and the real-world complications became more serious, more frequent, or simply different from what patients and doctors were led to expect. That is why failure-to-warn claims remain central to this litigation, even with the preemption fight hanging over these cases.
Why the Trial Stimulator and Permanent Implant May Not Match
This is one of the most frustrating patterns we see in spinal cord stimulator cases, and one that juries will understand immediately.
The patient does the trial. The trial works. The pain drops. For the first time in months or years, there is real relief. The doctor says the numbers look good. Everyone agrees it is time to move forward with the permanent implant.
Then the permanent device goes in. And somewhere down the line, weeks, months, sometimes longer, the relief fades. The pain returns. The hardware shifts. The system fails. The patient is left with a device inside their body that no longer does what it was supposed to do.
The essence of the problem is that the trial was never designed to predict long-term performance. It was designed to get the patient to say yes. That is not an accident. Device manufacturers know that the trial period is the moment of decision. If the trial goes well, the patient moves forward. If it does not, they walk away. So the trial is engineered to succeed. Short duration. Controlled conditions. Maximum placebo effect. What it does not do is tell the patient whether the permanent implant will actually work six months or two years down the road.
Lawsuits now being filed challenge exactly this. We allege that the permanent device does not deliver the same results as the trial because the implanted system behaves differently over time, because the leads migrate or the hardware fails, or because the short-term trial window was never an honest preview of what permanent implantation would look like.
This matters because it reframes the entire case. The issue is not always that the patient got zero benefit. The issue is that the trial created false confidence in a treatment that the permanent device could not actually deliver. The patient did everything right. Followed the process and trusted the system. And ended up with the worst of both worlds. An invasive implant inside their body, and none of the long-term relief they were promised.
Our lawyers believe this will resonate with juries. A patient who agrees to surgery after a promising trial does not feel like someone who gambled and lost. That patient feels like someone who was told the system worked, saw it work with their own eyes, and then got burned when the permanent version failed to deliver. That is not an assumption of risk. That is a betrayal of trust.
What Will Spinal Stimulator Settlement Amounts Be?
When people ask about spinal stimulator settlement amounts, they are usually not asking out of curiosity. They are trying to understand whether the harm they suffered is being taken seriously and whether the legal system recognizes the scope of what went wrong. The truth is that spinal cord stimulator lawsuits are not really about chasing a number. They are intended to compensate for a cascade of losses that often follow implantation when these devices fail.
For many patients, the first injury is not the worst one. What follows can be months or years of repeat surgeries, hospitalizations, imaging studies, and failed attempts to fix a device that was supposed to reduce pain, not multiply it. Each revision surgery carries its own risks, costs, and recovery time. For some, the device never works as promised again. For others, it must be removed entirely, leaving them with permanent damage and no pain relief at all.
There is also a less visible cost that shows up in almost every serious case: loss of trust in the medical system. Patients often describe feeling dismissed when they report shocks, burning sensations, or worsening pain. They are told the symptoms are rare, expected, or unrelated, even as their quality of life steadily declines. That erosion of trust, combined with physical suffering and financial strain, is a core driver of these lawsuits.
Only after those realities are understood does it make sense to talk about settlement compensation and payouts. Higher spinal stimulator settlement amounts tend to be associated with cases involving clear, documented harm rather than temporary discomfort. The strongest cases often include multiple revision surgeries, complete explantation of the device, or injuries that permanently alter neurological function.
Predicting spinal stimulator settlement amounts at this stage of the game is pure folly. But victims want to know what their lawyers think about what the value of their case could be if all goes perfectly as hoped and planned. The chart below is a speculative framework that uses specific values to show how compensation and payouts can scale with injury severity.
- Number of surgeries, including revision and explantation
- Objective proof of migration, lead failure, overheating, or malfunction
- Neurologic injury or bowel or autonomic dysfunction
- Medical expenses, wage loss, and diminished earning capacity
- Permanency, credibility, and the jurisdiction where the case is filed
Are Quick Settlements Possible?
You do not want to bet on a quick settlement. But it does happen. A lawsuit filed in October alleged that a woman suffered severe and worsening injuries after receiving a spinal cord stimulator manufactured by Boston Scientific, claiming the device migrated, delivered painful electrical shocks, and failed to perform as promised. The complaint accused the company of selling a defective medical device and failing to warn patients and doctors about known risks, while also raising broader concerns about regulatory oversight.
The plaintiff alleged that the stimulator differed materially from the version originally approved by the FDA and that those changes increased the risk of harm without adequate testing or disclosure. The case fit into a growing wave of spinal cord stimulator litigation focusing less on surgical error and more on device design, post-approval modifications, and inadequate warnings.
This one was quick. The lawsuit was resolved with Boston Scientific reaching a settlement in December, less than 60 days after the suit was filed and before any meaningful pretrial discovery. shortly after the complaint was filed. The timing of the settlement is interesting because we are still getting a feel for how these cases will be defended and if many can settle without even filing a lawsuit.
Bringing a Spinal Cord Stimulator Lawsuit
If you or a loved one experienced complications after spinal cord stimulator implantation, including electrocution, burns, infections, neurological injury, or repeated surgeries, you may have legal options. Lawsuits seek compensation for medical costs, lost income, pain and suffering, and long-term disability, while holding manufacturers accountable for unsafe products and inadequate warnings.
Eligibility for Spinal Cord Stimulator Lawsuit
Patients who received a spinal cord stimulator expecting relief, but instead experienced serious complications, may have grounds to pursue a legal claim. The cases lawyers like us are looking for involve more than just a bad outcome or an unfortunate side effect. They raise broader questions about how these devices were designed, tested, marketed, and regulated in the first place.
You may qualify if you or a loved one had a spinal cord stimulator implanted and later suffered injuries such as infection, shocks, burns, device migration, neurological damage, bowel, or autonomic complications. You have the most viable claims. The upper-tier cases for settlement would involve victims who need repeated revision surgeries or complete device removal. In many cases, patients report they were never clearly warned that these risks were possible, let alone likely.
Eligibility does not depend on whether the device is still implanted, whether symptoms appeared immediately, or whether the manufacturer labeled the complication as “rare.” What matters is whether the device failed to perform as promised—or introduced dangers that were not adequately disclosed. Lawsuits often focus on whether manufacturers minimized known risks, overstated benefits, or continued selling devices that had changed in meaningful ways without proper safety review.
Families may also have claims in cases involving severe disability or death following implantation, particularly where complications cascaded rapidly and left little opportunity for intervention. These cases are not just about individual harm, but about accountability within a system that often favors speed, scale, and market share over long-term patient safety.
If you believe your injury was dismissed, normalized, or treated as an acceptable tradeoff, you are not alone. Many of the claims now moving through courts nationwide began the same way, with patients realizing too late that the full story was never told.
Contact Us About Spinal Cord Stimulator Lawsuits
Our firm is seeking spinal cord stimulator lawsuits nationwide. If you have suffered physical or mental harm as a result of a spinal cord stimulator, contact us today for a free case evaluation. Call us at 800-553-8082 or contact us online.